The launch of the technology helps to further enable the company’s “One-Stick Hospital Stay” initiative. BD announced this initiative more than two years ago in an effort to transform the patient experience.
With FDA 510(k) clearance, BD can now offer its new PIVO Pro needle-free blood collection device. It features design improvements to achieve the first and only compatibility with integrated and long peripheral IV catheters. That includes the Nexiva closed IV catheter system with NearPort IV access, expanding on current compatibilities. PIVO has been available with traditional short peripheral IV catheters since 2017.
BD said the new solution combines the clinical benefits shown with integrated systems. That includes longer dwell times and reduced catheter complications. It also features the ability to draw high-quality blood samples directly from a peripheral IV line with PIVO Pro. That reduces the need for additional needlesticks, aiding in the One-Stick Hospital Stay effort.
According to the company, this new launch drives the initiative forward across each of its three pillars. It helps to reduce unnecessary needlesticks, uses one IV line as a single access point and enables optimal maintenance of the IV line.
“The latest innovation to our PIVO portfolio helps expand needle-free blood collection to even more patients and clinicians as we continue to redefine the standard of care through our ‘One-Stick Hospital Stay’ vision,” said Eric Borin, worldwide president of Medication Delivery Solutions at BD. “This new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients.”
